Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH

Langerhans cell histiocytosis (LCH) is a systemic histiocytic disorder.[1][1] The clinical manifestations range from a benign single-system disease to severe multisystem disease (MS-LCH). MS-LCH that fails to respond to initial standard therapy has a poor prognosis,[2][2],[3][3] and optimal salvage